Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the Brazilian diabetes study: a prospective cohort of type 2 diabetes.
Barreto J, Wolf V, Bonilha I, Luchiari B, Lima M, Oliveira A, Vitte S, Machado G, Cunha J, Borges C, Munhoz D, Fernandes V, Kimura-Medorima ST, Breder I, Fernandez MD, Quinaglia T, Oliveira RB, Chaves F, Arieta C, Guerra-Júnior G, Avila S, Nadruz W, Carvalho LSF, Sposito AC; Brazilian Heart Study Group. Barreto J, et al. Among authors: bonilha i. Curr Med Res Opin. 2022 Apr;38(4):523-529. doi: 10.1080/03007995.2022.2043658. Epub 2022 Mar 2. Curr Med Res Opin. 2022. PMID: 35174749
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial.
Cintra RMR, Soares AAS, Breder I, Munhoz DB, Barreto J, Kimura-Medorima ST, Cavalcante P, Zanchetta R, Breder JC, Moreira C, Virginio VW, Bonilha I, Lima-Junior JC, Coelho-Filho OR, Wolf VLW, Guerra-Junior G, Oliveira DC, Haeitmann R, Fernandes VHR, Nadruz W, Chaves FRP, Arieta CEL, Quinaglia T, Sposito AC; ADDENDA-BHS2 trial investigators. Cintra RMR, et al. Among authors: bonilha i. Diabetol Metab Syndr. 2019 Jul 31;11:62. doi: 10.1186/s13098-019-0457-3. eCollection 2019. Diabetol Metab Syndr. 2019. PMID: 31384310 Free PMC article.
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC; EXCEED-BHS3 Trial Investigator. Breder I, et al. Among authors: bonilha i. Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. doi: 10.1177/2040622320959248. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 33062236 Free PMC article.
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Bonilha I, Oliveira DC, Breder JC, Cavalcante P, Moreira C, Moura FA, de Lima-Junior JC, do Carmo HRP, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T; ADDENDA-BHS2 trial investigators. Sposito AC, et al. Among authors: bonilha i. Cardiovasc Diabetol. 2021 Mar 26;20(1):74. doi: 10.1186/s12933-021-01264-z. Cardiovasc Diabetol. 2021. PMID: 33771149 Free PMC article. Clinical Trial.
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis.
Barreto J, Luchiari B, Wolf VLW, Bonilha I, Bovi TG, Assato BS, Breder I, Kimura-Medorima ST, Munhoz DB, Quinaglia T, Coelho-Filho OR, Carvalho LSF, Nadruz W, Sposito AC. Barreto J, et al. Among authors: bonilha i. Diagnostics (Basel). 2022 Mar 26;12(4):814. doi: 10.3390/diagnostics12040814. Diagnostics (Basel). 2022. PMID: 35453862 Free PMC article.
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Breder I, Wolf VLW, Soares AAS, de Carvalho LSF, Kimura-Medorima ST, Cintra RM, Barreto J, Munhoz DB, Cunha JS, Bonilha I, Coelho-Filho OR, Quinaglia T, Nadruz W, Guerra-Junior G, Muscelli E, Sposito AC; ADDENDA-BHS2 Trial Investigators. Breder I, et al. Among authors: bonilha i. Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19. Diabetes Metab. 2022. PMID: 34808345 Clinical Trial. No abstract available.
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Sposito AC, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo HR, Munhoz D, Oliveira D, Coelho-Filho OR, Coelho OR, Matos-Souza JR, Moura FA, de Carvalho LSF, Nadruz W, Quinaglia T, Kimura-Medorima ST; EXCEED-BHS3 Group. Sposito AC, et al. Among authors: bonilha i. Cardiovasc Diabetol. 2022 Aug 6;21(1):147. doi: 10.1186/s12933-022-01584-8. Cardiovasc Diabetol. 2022. PMID: 35933413 Free PMC article. Clinical Trial.
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.
Cintra RM, Nogueira AC, Bonilha I, Luchiari BM, Coelho-Filho OR, Coelho OR, Schwartzmann P, Muscellie E, Nadruz W, Carvalho LSF, Sposito AC. Cintra RM, et al. Among authors: bonilha i. J Clin Endocrinol Metab. 2021 Sep 27;106(10):3060-3067. doi: 10.1210/clinem/dgab428. J Clin Endocrinol Metab. 2021. PMID: 34125217
Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.
de Carvalho LSF, Nogueira ACC, Bonilha I, Luchiari B, Benchimol A, Couri CEB, Borges JL, Barreto J, Sposito AC. de Carvalho LSF, et al. Among authors: bonilha i. Front Cardiovasc Med. 2022 Apr 29;9:876795. doi: 10.3389/fcvm.2022.876795. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35571207 Free PMC article.
23 results